{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T19:05:04Z","timestamp":1785351904779,"version":"3.55.0"},"reference-count":26,"publisher":"BMJ","issue":"12","funder":[{"name":"Hunan Provincial Department of Finance and Education Project","award":["No. 33: (2050205-30299-50502)"],"award-info":[{"award-number":["No. 33: (2050205-30299-50502)"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81771546"],"award-info":[{"award-number":["81771546"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002767","name":"Hunan Provincial Science and Technology Department","doi-asserted-by":"publisher","award":["2018SK52508"],"award-info":[{"award-number":["2018SK52508"]}],"id":[{"id":"10.13039\/501100002767","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Clin Pathol"],"accepted":{"date-parts":[[2020,9,17]]},"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>To explore the expression of secretagogin (SCGN) in neuroendocrine carcinoma of the uterine cervix and analyse its relationship with clinicopathological characteristics and prognosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>From January 2010 to December 2017, 44 patients with cervical neuroendocrine carcinoma undergoing surgery were included in the study group, and 55 patients with cervical non-neuroendocrine carcinoma (including 30 cases of cervical squamous cell carcinoma and 25 cases of cervical adenocarcinoma) undergoing surgery were included in the control group. Immunohistochemical staining of SCGN was performed in both groups and compared with three common neuroendocrine markers, chromogranin A, synaptophysin (Syn) and CD56 in the study group. Detailed clinicopathological data of the two groups were analysed, and the patient survival in the study group was followed up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The positive expression of SCGN in cervical neuroendocrine carcinoma, cervical adenocarcinoma and squamous cell carcinoma was 65.9% (29\/44), 8% (2\/25) and 0%, respectively. The positive expression of SCGN in cervical neuroendocrine carcinoma was significantly higher than that in cervical adenocarcinoma and squamous cell carcinoma (\u03c7\n                      <jats:sup>2<\/jats:sup>\n                      =44.5, p&lt;0.001). There were no statistical differences among the positive expression of SCGN and three common neuroendocrine markers (p&gt;0.05 for all). The intensity of SCGN staining in patients with cervical neuroendocrine carcinoma with lymph node metastasis was significantly higher than that in patients without lymph node metastasis (p=0.020). However, there was no significant association between SCGN expression and survival among patients with cervical neuroendocrine carcinoma (p=0.633).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>SCGN is a new neuroendocrine marker for cervical neuroendocrine carcinoma, whose expression correlates with lymph node metastasis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jclinpath-2020-206889","type":"journal-article","created":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T17:25:19Z","timestamp":1602782719000},"page":"787-795","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":8,"title":["Expression and clinical significance of a new neuroendocrine marker secretagogin in cervical neuroendocrine carcinoma"],"prefix":"10.1136","volume":"74","author":[{"given":"Li","family":"Yu","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China"},{"name":"Department of Gynecology, Yiyang Central Hospital, Yiyang, Hunan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suye","family":"Suye","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinchun","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Pathology, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6947-1159","authenticated-orcid":false,"given":"Chun","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,10,15]]},"reference":[{"key":"2025120600375917000_74.12.787.1","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.ygyno.2016.12.003","article-title":"Neuroendrocrine tumors of the uterine cervix: a therapeutic challenge for gynecologic oncologists","volume":"144","author":"Gadducci","year":"2017","journal-title":"Gynecol Oncol"},{"key":"2025120600375917000_74.12.787.2","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-4447-x"},{"key":"2025120600375917000_74.12.787.3","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1586\/14737140.2015.1047767","article-title":"Challenges in the diagnosis and management of cervical neuroendocrine carcinoma","volume":"15","author":"Burzawa","year":"2015","journal-title":"Expert Rev Anticancer Ther"},{"key":"2025120600375917000_74.12.787.4","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2019-000504"},{"key":"2025120600375917000_74.12.787.5","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-018-0110-y"},{"key":"2025120600375917000_74.12.787.6","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0b013e318173570b"},{"key":"2025120600375917000_74.12.787.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2011.04.011"},{"key":"2025120600375917000_74.12.787.8","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.ygyno.2016.11.020","article-title":"A new marker, insulinoma-associated protein 1 (INSM1), for high-grade neuroendocrine carcinoma of the uterine cervix: analysis of 37 cases","volume":"144","author":"Kuji","year":"2017","journal-title":"Gynecol Oncol"},{"key":"2025120600375917000_74.12.787.9","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1002\/ijgo.12544","article-title":"Prognostic factors of FIGO stage I-IIA small-cell neuroendocrine carcinoma of the uterine cervix","volume":"142","author":"Ning","year":"2018","journal-title":"Int J Gynaecol Obstet"},{"key":"2025120600375917000_74.12.787.10","doi-asserted-by":"publisher","DOI":"10.1177\/1066896916643385"},{"key":"2025120600375917000_74.12.787.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.anndiagpath.2012.01.009"},{"key":"2025120600375917000_74.12.787.12","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.biopha.2018.01.147","article-title":"Overexpression of secretagogin promotes cell apoptosis and inhibits migration and invasion of human SW480 human colorectal cancer cells","volume":"101","author":"Yang","year":"2018","journal-title":"Biomed Pharmacother"},{"key":"2025120600375917000_74.12.787.13","doi-asserted-by":"publisher","DOI":"10.1159\/000091207"},{"key":"2025120600375917000_74.12.787.14","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.2305"},{"key":"2025120600375917000_74.12.787.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijgo.2009.02.012"},{"key":"2025120600375917000_74.12.787.16","first-page":"1079","article-title":"Clinicopathological characteristics and prognosis-related factors of gastric neuroendocrine carcinoma","volume":"37","author":"Xiaolin","year":"2017","journal-title":"Tumor"},{"key":"2025120600375917000_74.12.787.17","doi-asserted-by":"publisher","DOI":"10.1097\/IGC.0000000000000059"},{"key":"2025120600375917000_74.12.787.18","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/IGC.0b013e3181ce427b","article-title":"Unfavorable prognosis of small cell neuroendocrine carcinoma of the uterine cervix: a retrospective matched case-control study","volume":"20","author":"Lee","year":"2010","journal-title":"Int J Gynecol Cancer"},{"key":"2025120600375917000_74.12.787.19","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdm465"},{"key":"2025120600375917000_74.12.787.20","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1159\/000494538","article-title":"Clinicopathological aspects of small cell neuroendocrine carcinoma of the uterine cervix: a multicenter retrospective study and meta-analysis","volume":"50","author":"Xu","year":"2018","journal-title":"Cell Physiol Biochem"},{"key":"2025120600375917000_74.12.787.21","doi-asserted-by":"publisher","DOI":"10.1097\/IGC.0000000000000496"},{"key":"2025120600375917000_74.12.787.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2013.02.025"},{"key":"2025120600375917000_74.12.787.23","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-018-5147-2","article-title":"The clinicopathological features and treatment modalities associated with survival of neuroendocrine cervical carcinoma in a Chinese population","volume":"19","author":"Zhang","year":"2019","journal-title":"BMC Cancer"},{"key":"2025120600375917000_74.12.787.24","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-006-0263-9"},{"key":"2025120600375917000_74.12.787.25","first-page":"2223","article-title":"Secretagogin, a marker for neuroendocrine cells, is more sensitive and specific in large cell neuroendocrine carcinoma compared with the markers CD56, CGA, syn and napsin a","volume":"19","author":"Dong","year":"2020","journal-title":"Oncol Lett"},{"key":"2025120600375917000_74.12.787.26","first-page":"24","article-title":"[Association of neuroendocrine differentiation with progression and prognosis of gastric adenocarcinoma]","volume":"45","author":"Xu","year":"2016","journal-title":"Zhejiang Da Xue Xue Bao Yi Xue Ban"}],"container-title":["Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jclinpath-2020-206889","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T08:38:08Z","timestamp":1765010288000},"score":1,"resource":{"primary":{"URL":"https:\/\/jcp.bmj.com\/lookup\/doi\/10.1136\/jclinpath-2020-206889"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,15]]},"references-count":26,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2021,11,19]]},"published-print":{"date-parts":[[2021,12]]}},"alternative-id":["10.1136\/jclinpath-2020-206889"],"URL":"https:\/\/doi.org\/10.1136\/jclinpath-2020-206889","relation":{},"ISSN":["0021-9746","1472-4146"],"issn-type":[{"value":"0021-9746","type":"print"},{"value":"1472-4146","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,15]]}}}